Pharma pumps up lobbying spend

Share this article:

The pharmaceutical industry increased its lobbying presence during the first quarter of this year. Roll Call's Political MoneyLine blog notes that Pfizer, Johnson & Johnson, Bayer and Merck were at the top of the list of pharma companies whose lobbying outlays were up from the fourth quarter of 2013.

Among the increases:

Pfizer upped its lobbying efforts this quarter by almost 53%, to $3.9 million, compared to $2.1 million in the fourth quarter, while Novartis put close to $2.6 million toward lobbying in the first quarter, compared to $920,000 in the fourth quarter of last year.

J&J dialed up its efforts, to $2.1 million, up from $860,000, and Merck more than doubled its efforts, with $2 million this quarter, compared to $820,000 last quarter.

But some drugmakers dialed back their efforts: Bristol-Myers Squibb proffered $520,000 during the first quarter, down from $740,000 last quarter, while Novo Nordisk reduced its outlay to $710,000, compared to $820,000 last quarter.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.